
About
remynd develops oral treatments for age-related neurodegenerative diseases, including Alzheimer’s disease, Huntington’s disease, and ALS-related mitochondrial dysfunction. It is based in the Arenberg Science Park in Leuven (Heverlee), Belgium, and has provided CRO services using proprietary mouse models.
Services
CRO services for neurodegenerative disease programs
Assesses the effects of experimental Alzheimer’s and other neurodegenerative disease treatments in proprietary mouse models.
Alzheimer’s program
Develops first-in-class oral treatments aimed at symptomatic benefit and disease modification by restoring synaptic function and reducing Aβ and tau pathology over time.
Huntington’s program
Develops first-in-class oral treatments that restore cortico-striatal transmission by targeting oxidative stress.
Discovery program for ALS
Addresses mitochondrial dysfunction as part of remynd’s discovery work in amyotrophic lateral sclerosis.
Capabilities
- Assays and studies
- Antibodies
- Rodent models
- In-vivo proof-of-concept
- Symptomatic benefit assessment
- Disease-modification assessment
- Therapeutic areas
- Alzheimer’s disease
- Huntington’s disease
- Amyotrophic lateral sclerosis (ALS)
- Neurodegenerative diseases
Modalities and species
- Modalities
- Antibody
- Species and models
- Mouse models
Details
- Type
- CRO
- Address
- Geenslaan 1 BE-3001 Leuven (Heverlee) T
- Sites
- Leuven (Heverlee), Belgium
- Serves
- US, Europe, Japan
- General enquiry
- info@remynd.com on their site